Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis

Citation

Published Version
doi:10.1073/pnas.1009179107

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13065008

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis

George Trichonas, Yusuke Murakami, Aristomenis Thanos, Yuki Morizane, Maki Kayama, Christine M. Debouck, Toshio Hisatomi, Joan W. Miller, and Demetrios G. Vavvas

*Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, MA 02114; †Department of Ophthalmology, Harvard Medical School, Boston, MA 02114; ‡Tetralogic Pharmaceuticals, Malvern, PA 19355; and †Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

Edited by Patricia K. Donahoe, Massachusetts General Hospital, Boston, MA, and approved October 25, 2010 (received for review June 30, 2010)

Apoptosis has been shown to be a significant form of cell loss in many diseases. Detachment of photoreceptors from the retinal pigment epithelium, as seen in various retinal disorders, causes photoreceptor loss and subsequent vision decline. Although caspase-dependent apoptotic pathways are activated after retinal detachment, caspase inhibition by the pan-caspase inhibitor Z-VAD fails to prevent photoreceptor death; thus, we investigated other pathways leading to cell loss. Here, we show that receptor interacting protein (RIP) kinase-mediated necrosis is a significant mode of photoreceptor cell loss in an experimental model of retinal detachment and when caspases are inhibited, RIP-mediated necrosis becomes the predominant form of death. RIP3 expression, a key activator of RIP1 kinase, increased more than 10-fold after retinal detachment. Morphological assessment of detached retinas treated with Z-VAD showed decreased apoptosis but significantly increased necrotic photoreceptor death. RIP1 kinase inhibitor necrostatin-1 or RIP3 deficiency substantially prevented those necrotic changes and reduced oxidative stress and mitochondrial release of apoptosis-inducing factor. Thus, RIP kinase-mediated programmed necrosis is a redundant mechanism of photoreceptor death in addition to apoptosis, and simultaneous inhibition of RIP kinases and caspases is essential for effective neuroprotection and may be a novel therapeutic strategy for treatment of retinal disorders.

Photoceptor death and subsequent visual decline occurs when the photoreceptors are separated from the underlying retinal pigment epithelium. Physical separation of photoreceptors is seen in various retinal disorders, including age-related macular degeneration (1), diabetic retinopathy (2), as well as rhegmatogenous i.e., caused by a break in the retina) retinal detachment (3, 4). Although surgery is carried out to reattach the retina, only two-thirds of patients with rhegmatogenous retinal detachment involving the macula, a region essential for central vision, recover 20/40 or better vision because of photoreceptor death (4, 5). Thus, identification of the mechanisms that underlie photoreceptor death is critical to developing new treatment strategies for these diseases.

Apoptosis and necrosis are two major cell death modalities (6). Apoptosis is a highly regulated process involving the caspase family of cysteine proteases. In contrast, necrosis has been considered a passive, unregulated form of cell death; however, recent evidence indicates that some necrosis can be induced by regulated signal transduction pathways such as those mediated by receptor interacting protein (RIP) kinases, especially in conditions in which caspases are inhibited or cannot be activated efficiently (7, 8). Stimulation of the Fas and TNFR family of death domain receptors is known to mediate apoptosis in most cell types through the activation of the extrinsic caspase pathway. In addition, in certain cells deficient for caspase-8 or treated with the pan-caspase inhibitor Z-VAD, stimulation of death domain receptors causes a RIP1 kinase-dependent programmed necrotic cell death instead of apoptosis (9, 10). This unique mechanism of cell death is termed programmed necrosis or necroptosis (11).

RIP1 is a serine/threonine kinase that contains a death domain and forms a death signaling complex with the Fas-associated death domain domain and caspase-8 in response to death domain receptor stimulation (12). During death domain receptor-induced apoptosis, RIP1 is cleaved and inactivated by caspase-8, the process of which is prevented by caspase inhibition (13). It has been unclear how RIP1 kinase mediates programmed necrosis, but recent studies revealed that the expression of RIP3 and the RIP1–RIP3 binding through the RIP homotypic interaction motif is a prerequisite for RIP1 kinase activation, leading to reactive oxygen species (ROS) production and necrotic cell death (14–16). In a rodent model of retinal detachment, we have shown that TNF-α expression levels increase substantially (17) and that caspases are activated after retinal detachment (18, 19). However, caspase inhibition by Z-VAD fails to prevent the retinal detachment-induced photoreceptor death (20). By using a combination of morphological, biochemical, genetic, and pharmacological investigations, the current study demonstrates that programmed necrosis is an essential and redundant mediator of photoreceptor death after retinal detachment. In addition, in the presence of the pan-caspase inhibitor Z-VAD, necrosis becomes the predominant form of photoreceptor cell loss. We further identified RIP kinases as a therapeutic target to prevent photoreceptor loss after retinal detachment.

Result

Increased Expression of RIP3 and RIP1 After Retinal Detachment. RIP3 is a key regulator of RIP1 kinase activation (21), and its expression level has been shown to correlate with responsiveness to programmed necrosis (14). We assessed the expression of RIP3 and RIP1 mRNA in the retina 3 d after retinal detachment by quantitative real-time PCR. This time point was chosen because photoreceptor death peaks at 3 d after retinal detachment (20). RIP3 expression increased 12-fold after retinal detachment compared with that in untreated retina (P = 0.0003; Fig. 1A). RIP1 expression also increased twofold (P = 0.0031; Fig. 1B). Western blot analysis confirmed that RIP3 protein expression increased more than 10-fold after retinal detachment (P = 0.0209; Fig. 1C). In...
situ hybridization showed that RIP3 signal was detected in neurosensory retina, especially in outer nuclear layer (ONL), after retinal detachment (Fig. S1). These data suggest that RIP-mediated programmed necrosis may be involved in the photoreceptor loss after retinal detachment.

**RIP1 Kinase Inhibitor Prevents Retinal Detachment-Induced Photoreceptor Death only in Combination with Caspase Inhibitor.** Necrostatin-1 (Nec-1) is a potent and selective inhibitor of programmed necrosis, which targets RIP1 kinase activity (10). RIP1 is phosphorylated at several serine residues in its kinase domain during programmed necrosis and Nec-1 inhibits this phosphorylation (10, 15). To further investigate the role of RIP1 kinase in retinal detachment-induced photoreceptor death, we first assessed the phosphorylation status of RIP1 by immunoprecipitating RIP1 from the retina (Fig. S2A) and then blotting with anti-phosphoserine antibody. Nec-1 (400 μM) and/or Z-VAD (300 μM) were injected subretinally at the time of retinal detachment induction. The dose of compounds was selected based on pilot studies that established that the half-life of the compound is approximately 6 h in the subretinal space. After retinal detachment, RIP1 phosphorylation was elevated especially in Z-VAD-treated retina compared with untreated retina (Fig. S2B). Importantly, Nec-1 plus Z-VAD treatment substantially inhibited this increase of RIP1 phosphorylation (Fig. S2B).

We next examined photoreceptor death by TUNEL 3 d after retinal detachment. Treatment with Nec-1 or Z-VAD alone showed no significant effect on the number of TUNEL-positive cells in ONL (1,067.5 ± 39.5 cells per mm² and 1,134.7 ± 297.5 cells per mm², respectively) compared with vehicle treatment (1,366.3 ± 103.7 cells per mm²; Fig. 2A and B). In comparison, combined treatment with Nec-1 and Z-VAD significantly reduced the number of TUNEL-positive cells in ONL (573.3 ± 154.3 cells per mm²; P < 0.05; Fig. 2A and B). The appearance of TUNEL-positive cells was decreased to approximately 200 cells per mm² in each group 5 d after retinal detachment (Fig. 2B). Although detection of DNA fragmentation by TUNEL is used as a marker of apoptosis, it has been reported that necrosis, programmed or otherwise, also yields DNA fragments that react with TUNEL in vivo, rendering it difficult to discriminate between apoptosis and necrosis (22). We next measured the thickness ratio of ONL to the total retinal thickness in detached retina compared with normal attached retina. Treatment with Nec-1 or Z-VAD alone had no protective effect on the reduction of ONL thickness ratio, whereas Nec-1 plus Z-VAD treatment significantly prevented the reduction in retinal thickness 3 and 5 d after retinal detachment (P < 0.05; Fig. 2A and C). More importantly, treatment with Nec-1 plus Z-VAD showed efficient neuroprotection even when these compounds were injected intravitreally 1 d after retinal detachment induction (P < 0.05; Fig. S3). To further establish the specificity of RIP1 and caspase inhibitor, we assessed the effect of another necrostatin (Nec-4) (23) and/or pan-caspase inhibitor (PCI) (24) on retinal detachment-induced photoreceptor death. Nec-4 or PCI alone did not show any neuroprotective effect, whereas Nec-4 plus PCI treatment significantly suppressed photoreceptor loss after retinal detachment (P < 0.05; Fig. S4). These data suggest that RIP1 kinase is an important mediator of photoreceptor death after retinal detachment, especially in the presence of pan-caspase inhibitor.

**Caspase Inhibition Shifts Retinal Detachment-Induced Photoreceptor Death from Apoptosis to Programmed Necrosis.** We next examined the morphology of photoreceptors after retinal detachment by transmission EM (TEM) and analyzed the change with Nec-1 and Z-VAD treatment. Photoreceptors showing cellular shrinkage and nuclear condensation were defined as apoptotic cells, whereas photoreceptors associated with cellular and organelle swelling and discontinuities in nuclear and plasma membrane were defined as necrotic cells. The presence of electron-dense granular materials were reported to occur subsequent to both apoptotic and necrotic cell death and cells with these findings were labeled simply as end-stage cell death/unclassified (25, 26). On day 3 after retinal detachment, the photoreceptor death caused by apoptosis was almost twice that caused by necrosis in vehicle-treated retina (21.7 ± 1.3% apoptotic cells, 13.3 ± 1.0% necrotic cells, 4.4 ± 1.4% unclassified; Fig. 3A and E). Nec-1 treatment did not affect the percentage of apoptotic and necrotic cells after retinal detachment (19.8 ± 2.0% apoptotic cells, 13.1 ± 1.4% necrotic cells, 2.8 ± 0.4% unclassified; Fig. 3B and E). In comparison, Z-VAD treatment significantly decreased apoptotic photoreceptor death and increased necrotic cell death (11.4 ± 1.2% apoptotic cells, 21.9 ± 2.3% necrotic cells, 5.6 ± 1.4% unclassified; P < 0.05; Fig. 3C and E). However, Nec-1 combined with Z-VAD substantially prevented the switch to necrotic cell death and led to a decrease in both forms of cell loss.
(6.9 ± 2.9% apoptotic cells, 9.8 ± 0.7% necrotic cells, 1.0 ± 0.2% unclassified; P < 0.01; Fig. 3 D and E).

Consistent with the EM findings, subretinal injection of propidium iodide (PI) before enucleation, a technique to demarcate cells with disrupted cell membrane (27), showed increased number of PI-positive photoreceptors in Z-VAD-treated retina compared with vehicle-treated retina 3 d after retinal detachment (P < 0.05; Fig. S5 A and B). Treatment with Nec-1 plus Z-VAD significantly suppressed the number of PI-positive cells in ONL (P < 0.05; Fig. S5 A and B).

Collectively, these data indicate that necrosis as well as apoptosis is involved in photoreceptor death after retinal detachment, and that RIP1 kinase-mediated necrosis becomes a predominant form of the photoreceptor death when caspase-dependent apoptotic pathway is inhibited.

**Rip3 Deficiency Inhibits Induction of Programmed Necrosis and Prevents Photoreceptor Death After Retinal Detachment.** To analyze further the role of RIP kinases in retinal detachment-induced photoreceptor death, we caused retinal detachment in mice deficient for Rip3, a key regulator of RIP1 kinase activation (21). Without retinal detachment, the morphology of retina and ONL thickness ratio were similar in Rip3−/− and WT mice. Three days after retinal detachment, Rip3−/− mice showed significantly fewer TUNEL-positive cells (804.7 ± 204.5 cells per mm2) than WT mice (1,668.7 ± 305.8 cells per mm2; P < 0.01; Fig. 4 A and B). In contrast to WT animals, Z-VAD treatment in Rip3−/− mice further decreased TUNEL-positive cells after retinal detachment (407.7 ± 188.9 cells per mm2; P < 0.05 vs. Rip3−/− mice with vehicle), whereas Nec-1 did not provide any additional effect (786.7 ± 278.7 cells per mm2; Fig. 4 A and B). Rip3−/− retinas exhibited preserved ONL thickness ratio, which was augmented by Z-VAD treatment, on days 3 and 5 after retinal detachment (Fig. 4 C).

We next performed morphological assessment of the Rip3−/− retina after retinal detachment by TEM. In WT mice, the percentage of necrotic photoreceptors was significantly increased by Z-VAD treatment (13.3 ± 1.5% apoptotic cells, 22.1 ± 1.0% necrotic cells, 1.0 ± 0.6% unclassified) compared with vehicle treatment (22.2 ± 4.0% apoptotic cells, 13.0 ± 2.1% necrotic cells, 2.5 ± 1.3% unclassified; P < 0.05; Fig. 4 A and B). In contrast, in Rip3−/− mice, Z-VAD treatment substantially prevented photoreceptor death after retinal detachment without inducing necrotic cell death (4.8 ± 1.3% apoptotic cells, 6.4 ± 1.3% necrotic cells, 0.9 ± 0.4% unclassified). Consistent with these results, the number of photoreceptors with disrupted plasma membrane, as assessed by in vivo PI labeling, was not increased by Z-VAD treatment in Rip3−/− retinas (Fig. S5 C and D), confirming that Rip3 plays an essential role to induce programmed necrosis after retinal detachment, especially in the presence of caspase inhibitor. In addition, unexpectedly, Rip3−/− retinas showed fewer apoptotic cells after retinal detachment (13.4 ± 1.1% apoptotic cells, 8.1 ± 1.0% necrotic cells, 1.2 ± 0.5% unclassified) compared with WT retinas, suggesting that Rip3 may be involved not only in RIP1-mediated programmed necrosis but also in other cell death pathways. Alternatively, the kinetics of a single administration of Nec-1 to inhibit RIP1 kinase are different from the chronic loss of RIP kinase activity in Rip3−/− animals.

As the release of intracellular content in necrosis results in secondary inflammation, we next analyzed the inflammatory reaction after retinal detachment by immunofluorescence detection of the macrophage/microglial marker CD11b. On day 3 after retinal detachment, Z-VAD-treated eyes demonstrated greater infiltration of CD11b-positive cells in the detached retina compared with vehicle-treated eyes (P < 0.05; Fig. 6 A and B), suggesting that necrotic cell death may promote inflammatory reaction. This increase of CD11b-positive cells by Z-VAD was significantly suppressed with Nec-1 plus Z-VAD treatment or Rip3 deficiency (P < 0.01; Fig. 6 A and B). Moreover, CD11b-positive cells by Z-VAD was significantly suppressed with Nec-1 plus Z-VAD treatment or Rip3 deficiency (P < 0.01; Fig. 6 A and B). We previously described that monocyte chemotactic protein 1 (MCP-1) is an essential mediator of early infiltration of macrophage/microglia and the subsequent cell death after retinal detachment (28). However, Nec-1 plus Z-VAD did not affect MCP-1 expression (Fig. 6 C). Rip3−/− retinas also showed substantial up-regulation of MCP-1 after retinal detachment, although its expression level was slightly decreased compared with WT retinas (Fig. 6 D).

**RIP Kinases Mediate ROS Production and Apoptosis-Inducing Factor Nuclear Translocation After Retinal Detachment.** Recent studies reported that RIP kinases regulate downstream ROS production during programmed necrosis (15, 16, 29). To examine the oxidative retinal damage following retinal detachment, we used ELISA for carbonyl adducts of proteins. On day 3 after retinal detachment, PNAS | December 14, 2010 | vol. 107 | no. 50 | 21697
detachment, the retina treated with vehicle or Z-VAD exhibited significant increase of carbonyl contents compared with untreated retina (P < 0.05; Fig. 7A). In contrast, Nec-1 plus Z-VAD treatment almost completely suppressed the increase of carbonyl contents after retinal detachment (P < 0.05; Fig. 7A). Rip3−/− retinas also showed significantly less carbonyl contents after retinal detachment compared with WT retinas (P < 0.01; Fig. 7B).

Apoptosis-inducing factor (AIF) is a caspase-independent inducer of cell death, which is released from the mitochondria and translocates into the nuclei during cell death (30). We previously described that mitochondrial release of AIF is a critical event for the photoreceptor death after retinal detachment (20, 31). Because ROS overproduction is known to induce mitochondrial membrane permeabilization and AIF release (32), we next examined the cellular localization of AIF by immunofluorescence. AIF translocation into TUNEL-positive photoreceptor nuclei was increased after retinal detachment; whereas Nec-1 plus Z-VAD treatment or Rip3 deficiency substantially reduced AIF nuclear translocation (P < 0.01; Fig. 7 C–F). These data demonstrate that ROS production and AIF nuclear translocation are downstream events of RIP signaling.

Discussion
Photoreceptor death after retinal detachment has been thought to be caused mainly by apoptosis (3, 4). Although caspase-dependent pathway is known to be activated after retinal detachment, caspase inhibition by pan-caspase inhibitor fails to prevent photoreceptor death (18, 20). In this study, we investigated other pathways leading to photoreceptor death, and demonstrated that necrotic photoreceptor death occurs after retinal detachment, although its frequency is approximately half that of apoptosis. Consistent with our findings, Arimura et al. showed that the vitreous level of high-mobility group box1 protein, which is known to be released from necrotic cells but not apoptotic cells, is increased in human eyes with retinal detachment (33, 34). Furthermore, we found that Z-VAD treatment decreases apoptosis but increases necrotic photoreceptor death after retinal detachment, and that Nec-1 cotreatment effectively suppresses necrotic photoreceptor death. These findings clearly demonstrate programmed necrosis as an essential and complementary mechanism of photoreceptor death, which is further revealed when caspasas are inhibited (Fig. 8). In other retinal degenerative conditions such as inherited retinal degeneration and light-induced retinal injury, it has been shown that the photoreceptor death is not prevented by Z-VAD (35–37), and thus it may be possible that programmed necrosis may underlie the death execution in these diseases as well.

RIPL1 is an adaptor kinase that acts downstream of death domain receptors and is essential for both cell survival and death (38). The kinase activity of RIP1 is crucial for programmed necrosis, but dispensable for prosurvival NF-κB activation (9, 10, 39). Consistent with these results, Nec-1 inhibited RIP1 phosphorylation, which was increased by Z-VAD after retinal detachment, but showed no effect on NF-κB p65 phosphorylation (Fig. S6). RIP1 switches function to a regulator of cell death when

Fig. 5. Rip3 deficiency inhibits induction of programmed necrosis and prevents photoreceptor death after retinal detachment. (A) TEM photomicrographs in the ONL on day 3 after retinal detachment in WT and Rip3−/− retina treated with vehicle, Nec-1, Z-VAD, or Nec-1 plus Z-VAD. In untreated attached retina, the retinal morphology was similar in WT and Rip3−/− mice. A, apoptotic cell; N, necrotic cell. (B) Quantification of apoptotic and necrotic photoreceptor death after retinal detachment (n = 4 each). Rip3 deficiency inhibits the switch to necrotic cell death by Z-VAD treatment and prevents photoreceptor death after retinal detachment. (Scale bar, 5 μm.)

Fig. 6. Effect of RIP pathways on inflammatory response after retinal detachment. (A and B) Immunofluorescence for CD11b (A) and quantification of <CD11b-positive macrophage/microglia in WT and Rip3−/− retina after retinal detachment. In WT mice, Z-VAD treatment significantly increased infiltration of CD11b-positive cells compared with vehicle treatment (P < 0.05). This increase of CD11b-positive cells was significantly suppressed with Nec-1 plus Z-VAD treatment or Rip3 deficiency (P < 0.01). (Scale bar, 50 μm.) (C and D) ELISA for MCP-1 on day 3 after retinal detachment in retina treated with vehicle (n = 5), Z-VAD (n = 5), or Nec-1 plus Z-VAD (n = 6) (C) and in WT and Rip3−/− retina (n = 5 each) (D). The retinas without retinal detachment were used as controls. *P < 0.05; **P < 0.01; NS, not significant.
it is unubiquitinated and forms a death signaling complex (40, 41). In addition, recent studies revealed that formation of RIP1–RIP3 complex is a critical step in the RIP1 kinase activation and induction of programmed necrosis (14–16). After retinal detachment, RIP3 expression increased more than 10-fold and Rip3 deficiency prevented the shift to necrotic photoreceptor death by Z-VDAD, implying that RIP3 is a key regulator of programmed necrosis after retinal detachment.

TNF-α and Fas-L are potent inducer of programmed necrosis as well as apoptosis (11). After retinal detachment, TNF-α was increased in detached retina (Fig. S7 A and B) and treatment with neutralizing anti-TNF-α antibody suppressed photoreceptor loss (Fig. S7 C and D), suggesting that TNF-α may contribute to the induction of apoptosis and programmed necrosis. In addition to TNF-α, Fas-L/Fas pathway is known to be activated and mediate photoreceptor death after retinal detachment (19, 42), and may cooperate with TNF-α to activate RIP kinases and promote programmed necrosis in addition to apoptosis. Thus, RIP kinases act as common intermediaries for various upstream death signals and their blockade in addition to caspases is likely necessary for effective neuroprotection (Fig. S8).

Overproduction of ROS has been implicated in mitochondrial dysfunction and programmed necrosis (43, 44). NADPH oxidase 1 forms a complex with RIP1 and generates superoxide during programmed necrosis (29). Alternatively, RIP3 activates metabolic enzymes such as glutamate dehydrogenase 1, and thereby increases mitochondrial ROS production (16). Consistent with these reports, ROS production after retinal detachment was suppressed by RIP kinase inhibition. In addition, our data show that RIP kinases act upstream of AIF nuclear translocation. Recent studies demonstrate that AIF is an essential mediator of programmed necrosis induced by alkylating DNA damage (45). These results link RIP kinases, AIF translocation, and programmed necrosis.

Cell death and inflammation communicate with each other during neurodegeneration (46). Infiltrating inflammatory cells stimulate neuronal cell death (28), and conversely dying cells, especially of the necrotic form, trigger inflammation (47). We previously described that MCP-1 is a key mediator of early infiltration of macrophage/microglia after retinal detachment (28). However, MCP-1 up-regulation after retinal detachment was not substantially altered by Nec-1 plus Z-VDAD or Rip3 deficiency, suggesting that RIP kinases are not involved in the initiation of inflammation. Our in situ hybridization data suggest that RIP3 is detected in ONL after retinal detachment, suggesting that RIP kinase inhibition may target photoreceptors and suppress inflammation subsequent to photoreceptor death. However, as RIP3 is known to be expressed in several cell types including macrophages (48), and given the limited resolution of our in situ hybridization, we cannot exclude the possibility that RIP kinase inhibition may affect macrophage/microglia function; defining the role of RIP kinases in cell death and inflammation warrants further studies using tissue-specific Rip3 knockouts.

Photoreceptor loss occurs acutely after retinal detachment, and the visual acuity of patients with rheumatogenous retinal detachment is not always restored after successful reattachment surgery. In other retinal disorders—including the most and second-most common causes of blindness in the adults of the western world, age-related macular degeneration and diabetic retinopathy—detachment of retinal photoreceptors persists chronically and vision loss progresses. Thus, neuroprotective agents preventing photoreceptor loss may open a novel therapeutic approach to the treatment of these diseases. Unfortunately, most promises of neuroprotection have not come to clinical fruition, likely because most of the work on this field has been focused on monotherapy. In this work, we identify RIP-mediated programmed necrosis as an essential pathway for cell loss, which acts in concert with caspase-dependent apoptosis. Simultaneous inhibition of both RIP1 kinase and caspase pathways with small molecule compounds provides significant protection of photoreceptors after photoreceptor detachment and may be used as a therapeutic strategy for preventing...
vision deficit in various retinal disorders associated with photoreceptor loss.

Materials and Methods

Animals and Reagents. All animal experiments adhered to the statement of the Association for Research in Vision and Ophthalmology, and protocols were approved by the Animal Care Committee of the Massachusetts Eye and Ear Infirmary. Adult male Brown Norway rats and WT C57BL/6 mice were purchased from Charles River. Rips3−/− mice were provided from D. M. Dicht (Genentech, South San Francisco, CA) and backcrossed to C57BL/6 mice (4B). Nec-1 was provided by J. Yuan (Harvard Medical School, Boston, MA). Z-VAD was purchased from Alexius.

Induction of Retinal Detachment, TUNEL, and Evaluation of ONL Thickness Ratio. Experimental retinal detachment was induced as previously described (20). TUNEL and quantification of TUNEL-positive cells in ONL were performed as previously described (28). The ratio of ONL thickness to the total retinal thickness was determined by ImageJ software and standardized by that in the attached retina. Five sections were randomly selected in each eye, and the central area of detached retina and the midperipheral region of attached retina were photographed. Then, the ONL thickness ratio was measured at 10 points in each section by masked observers. The data are expressed as normalized ONL thickness ratio: [ONL / neuroretina thickness in detached retina] / [ONL / neuroretina thickness in attached retina].

Statistical Analysis. All values were expressed as the mean ± SD. Statistical differences between two groups were analyzed by Mann–Whitney U test. Multiple group comparison was performed by ANOVA followed by Tukey-Kramer adjustments. Differences were considered significant at P < 0.05. A detailed description of methods is provided in SI Materials and Methods.

Acknowledgments. We thank N. Michaud (Massachusetts Eye and Ear Infirmary) and F. Morikawa (Kyushu University) for technical assistance. This work was supported by the Baccardi Fund (D.G.V.), the Research to Prevent Blindness Foundation (D.G.V.), the National Eye Institute Grant EYO14104 (Massachusetts Eye and Ear Infirmary core grant).

References

Supporting Information

Trichonas et al. 10.1073/pnas.1009179107

SI Materials and Methods

Surgical Induction of Retinal Detachment. Experimental retinal detachment was induced as previously described (1). Briefly, a 30-gauge needle was inserted into the subretinal space via an external transscleral transchoroidal approach, and 1% sodium hyaluronate (Provisc; Alcon) containing vehicle (0.05% DMSO and 0.8% cyclodextrin in PBS solution), Nec-1 (400 µM), and/or Z-VAD (300 µM; Alexis) was gently injected into the subretinal space to enlarge the retinal detachment.

Immunofluorescence. Immunofluorescence was performed as previously reported (2). The enucleated eyes were frozen in optimal cutting temperature compound (Sakura Finetechnical). Five-micrometer-thick sections were cut, air-dried, and fixed in cold acetone for 10 min. Rabbit anti-AIF (1:100; Cell Signaling Technology) and rat anti-CD11b (1:50; BD Biosciences) were used as primary antibodies and incubated at 4°C overnight. A nonimmune serum was used as a negative control. Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 594-conjugated goat anti-rat IgG (Invitrogen) were used as secondary antibodies and incubated at room temperature for 1 h. The specimens were imaged by confocal microscopy using a Leica HCX APOL 40x lens.

In Situ Hybridization. Partial sequence of mouse RIP3 gene was amplified by RT-PCR using AGCACAGGACACATCAGTTGG and CTTGAGGCAGTAATCTCTGTG, and cloned into the pCR-II vector (Invitrogen). Digoxigenin-labeled riboprobe was synthesized in vitro (Invitrogen). Hybridization signals were visualized with BM purple AP substrate (Roche). Hybridization signals were visualized with BM purple AP substrate (Roche).

TEM. TEM was performed as previously described (1). More than 200 photoreceptors per eye were photographed and subjected to quantification of cell death modes in a masked fashion. Photoreceptors showing cellular shrinkage and nuclear condensation were defined as apoptotic cells, whereas photoreceptors associated with cellular and organelle swelling and discontinuities in plasma and nuclear membrane were defined as necrotic cells. Electron-dense granular materials were labeled simply as end-stage cell death/unclassified, because these materials are reported to occur subsequent to both apoptotic and necrotic cell death (3, 4).

RNA Extraction, RT-PCR, and Quantitative Real-Time PCR. Total RNA extraction and reverse transcription were performed as previously reported (1, 5). A real-time PCR assay was performed with the Prism 7700 Sequence Detection System (Applied Biosystems). TaqMan gene expression assays were used to check the expression of RIP1 (Rn01757378_m1), RIP3 (Rn00595154_m1), and TNF-α (Rn99999017_m1). For relative comparison of each gene, we analyzed the Ct value of real-time PCR data with the ΔΔCt method normalizing by an endogenous control (18S ribosomal RNA).

ELISA. The protein contents in retinal extract were determined with ELISA kits for protein carbonyls (Cell Biolabs), MCP-1 [rat MCP-1 (Thermo Scientific), mouse MCP-1 (R&D Systems)], and TNF-α [rat TNF-α (Invitrogen), mouse TNF-α (R&D Systems)] according to manufacturer instructions.

Western Blotting. The vitreous and neural retina, combined, was collected on day 3 after retinal detachment. Samples were run on 4% to 12% SDS-polyacrylamide gel electrophoresis and transferred onto PVDF membrane. After blocking with 3% nonfat dried milk, the membrane was reacted with RIP3 (1:10,000, Sigma), RIP1 (1:2,000; BD Biosciences), phosphoserine (1:2,000, Enzo), or anti-phosphorylated NF-κB p65 (1:1,000; Cell Signaling Technology) antibody. They were then developed with enhanced chemiluminescence. Lane-loading differences were normalized by β-tubulin (1:1,000; Cell Signaling Technology).

Immunoprecipitation. Equal amount of retinal lysates (1 mg) were incubated with 1 µg anti-RIP1 antibody (BD Biosciences) and 20 µL of protein A/G agarose beads (Thermo Scientific) at 4°C overnight. Beads were washed five times with lysis buffer and Tris-buffered saline solution and the immunopellets were then subjected to Western blotting.

In Vivo PI Staining. Five microliters of PI (50 µg/mL) were injected into the subretinal space 3 d after retinal detachment. After 2 h, the eyes were enucleated and 10-µm-thick cryosections were cut, air-dried, and fixed in 100% ethanol. DAPI was used to counterstain the nuclei. The center of the detached retina was photographed with a fluorescence microscope, and the number of PI-positive cells in ONL was analyzed by ImageJ software.

Reagents. Goat anti-mouse/rat TNF-α blocking antibody was purchased from R&D Systems. The rat eyes were subretinally injected with 1% of sodium hyaluronate containing 0.1 mg/mL of anti-TNF-α antibody or control goat antibody. Nec-4 and PCI (IDN6556) were prepared as described in refs. 6 and 7, respectively.

In situ hybridization analysis of RIP3. RIP3 signal was detected in retinal tissue, especially in the ONL, after retinal detachment. The retina from Rip3−/− animals was used as negative control. GCL, ganglion cell layer; INL, inner nuclear layer. (Scale bar, 50 µm.)

(A) Immunoprecipitation of RIP1 from retinal lysates. One milligram of retinal lysates was incubated with anti-RIP1 antibody and protein A/G agarose beads. Extracts before (Pre) and after (Post) immunoprecipitation and the immunopellets (IP) were run on a 4% to 12% SDS/PAGE and blotted with anti-RIP1 antibody. Anti-RIP1 antibody alone was used as negative control. Extracts after immunoprecipitation showed almost complete immunodepletion of RIP1 from the retinal extract. (B) Phosphorylation of RIP1 after retinal detachment. RIP was immunoprecipitated from lysates of untreated retina and of retina 2 d after retinal detachment with treatment of vehicle, Nec-1, Z-VAD, or Nec-1 plus Z-VAD, and then assessed for phosphorylation by Western blotting. RIP1 phosphorylation was elevated especially in Z-VAD-treated detached retina, and this phosphorylation was inhibited by Nec-1 plus Z-VAD.

Quantification of TUNEL-positive photoreceptors (A) and ONL thickness ratio (B) on day 3 after retinal detachment in rats (n = 4–5). Five microliters of Nec-1 (2 mM) and/or Z-VAD (3 mM) were injected intravitreally 1 d after retinal detachment induction. Treatment with Nec-1 plus Z-VAD significantly decreased the number of TUNEL-positive cells and prevented the reduction of ONL thickness ratio after retinal detachment (*P < 0.05; **P < 0.01).
Fig. S4. Quantification of TUNEL-positive photoreceptors (A, C, and E) and ONL thickness ratio (B, D, and F) on day 3 after retinal detachment in rats (n = 5–6). Nec-4, PCI, and/or Z-VAD were injected subretinally at the indicated doses. Treatment with Nec4 or PCI alone did not show any protective effect (A–D). In contrast, Nec-4 plus Z-VAD or Nec-4 plus PCI treatment significantly suppressed photoreceptor loss after retinal detachment (E and F). **P < 0.01.
Fig. S5. PI staining (A and C) and quantification of PI-positive photoreceptors (B and D) on day 3 after retinal detachment in retina treated with vehicle, Z-VAD, or Nec-1 plus Z-VAD (n = 6 each; A and B) and in WT and Rip3−/− retina (n = 5–6; C and D); *P < 0.05; **P < 0.01. (Scale bar, 100 μm.)

Fig. S6. Western blot analysis for phospho-NFκB p65 in control retina without retinal detachment and in retina 3 d after retinal detachment with treatment of vehicle, Z-VAD, or Nec-1 plus Z-VAD. Lane-loading differences were normalized by the level of β-tubulin.
**Fig. S7.** (A) Quantitative real-time PCR analysis for TNF-α in control retina without retinal detachment (n = 9) and in retina 3 d after retinal detachment with treatment of vehicle (n = 9), Z-VAD (n = 8), or Nec-1 plus Z-VAD (n = 9). (B) ELISA for TNF-α in retina without retinal detachment (n = 5) and in retina 3 d after retinal detachment with treatment of vehicle (n = 5), Z-VAD (n = 5), or Nec-1 plus Z-VAD (n = 6). DAPI staining (C) and quantification of ONL thickness ratio (D) in detached retina treated with anti–TNF-α antibody, control antibody, or ZVAD plus Nec-1 on day 3 after retinal detachment (n = 4 each); *P < 0.05; **P < 0.01.

**Fig. S8.** Schematic of RIP signaling pathway. RIP1 mediates prosurvival NF-κB activation through polyubiquitination of RIP1 in response to TNF-α. When RIP1 is unubiquitinated, RIP1 switches function to a regulator of cell death. RIP1 forms a death signaling complex with Fas-associated death domain (FADD) and caspase-8 after stimulation of death domain receptors, and induces caspase-dependent apoptosis. In conditions in which caspase pathway is blocked, RIP1 kinase is activated in RIP1–RIP3 complex and promotes programmed necrosis. TRAF2, tumor necrosis factor-receptor associated signaling adaptor; TRADD, TNF receptor-associated death domain; cIAP, cellular inhibitor of apoptosis; CYLD, cylindromatosis.